Lercaprel

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lercaprel, are an ACE inhibitor and a calcium‑channel blocker presented as an oral tablet for systemic use. The combination is indicated for the treatment of essential hypertension in adult patients. GNH USA supplies Lercaprel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercaprel combines an ACE inhibitor and a calcium‑channel blocker to manage high blood pressure.

Essential hypertension: provides additive blood‑pressure reduction, helping patients achieve target blood‑pressure goals.

Lercaprel may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of the ankles or feet. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzyme elevations. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: irregular heart rhythms. - Neutropenia: significant reduction in white blood cells.

Before initiating Lercaprel, several safety considerations should be observed. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Electrolyte balance: check potassium and sodium levels, especially if using diuretics. - History of angioedema: avoid in patients with prior ACE‑inhibitor‑related swelling. - Pregnancy: use only if potential benefit justifies risk; data are limited. - Concomitant potassium‑sparing agents: evaluate risk of hyperkalaemia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercaprel can interact with several medicines; the significance varies.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined renin‑angiotensin blockade may increase renal risk. - Concurrent use of another ACE inhibitor or ARB: may cause excessive hypotension and renal impairment. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lercanidipine plasma levels. - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalaemia. - Neprilysin inhibitors (e.g., sacubitril): may amplify angioedema risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Thiazide or loop diuretics: may enhance hypotensive response. - Other antihypertensives: dose adjustments may be needed to avoid excessive blood‑pressure drop. - Grapefruit juice: can modestly raise lercanidipine concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lercanidipine efficacy.